<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunocompromised individuals, including those infected with human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV), are at increased risk of Epstein-Barr virus (EBV)-associated aggressive B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) or diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Differential diagnosis of these <z:hpo ids='HP_0002665'>lymphomas</z:hpo> requires histopathological, immunohistochemical and cytogenetic assessments </plain></SENT>
<SENT sid="2" pm="."><plain>Rapid, less invasive approaches to the diagnosis of EBV-associated B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are needed </plain></SENT>
<SENT sid="3" pm="."><plain>Here, high-throughput cytokine profiling of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines and EBV-transformed B lymphoblastoid cell lines (B-LCL), representing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, was carried out </plain></SENT>
<SENT sid="4" pm="."><plain>By monitoring the production of 42 different cytokines, unique cytokine signatures were identified for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and B-LCL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells produced interleukin (IL)-10, 10 kDa interferon gamma-induced protein (IP-10)/CXCL10, macrophage-derived chemokine (MDC)/CCL22, macrophage inflammatory protein (MIP)-1α/CCL3 and MIP-1β/CCL4 </plain></SENT>
<SENT sid="6" pm="."><plain>In addition to these five cytokines, the cytokine signature of B-LCL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cells included IL-8/CXCL8, IL-13, platelet-derived growth factor (PDGF)-AA, and regulated upon activation, <z:mpath ids='MPATH_458'>normal</z:mpath> T cell expressed and secreted (RANTES)/CCL5 </plain></SENT>
<SENT sid="7" pm="."><plain>Epstein-Barr virus latency was responsible for the increased production of IL-10, MDC/CCL22 and MIP-1α/CCL3 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells, suggesting that EBV-mediated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-genesis involves these three cytokines </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that high-throughput cytokine profiling might be a valuable tool for the differential diagnosis and might deepen our understanding of the pathogenesis of EBV-associated B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>